GSK, Novartis to close vax deal next week; NICE rejects Dendreon's Provenge;

> GlaxoSmithKline ($GSK) and Novartis ($NVS) are preparing to close their multi-billion-dollar asset swap--which will send most of Novartis' vaccines unit to Glaxo--in the week beginning March 2. Report

> The U.K.'s cost watchdogs have shot down Dendreon's ($DNDN) Provenge, the price is "too high for the benefit it may provide to patients." Report

> Protein Sciences has added Cardinal Health ($CAH) and McKesson ($MCK) as distributors for its flu vaccine, Flublok. Release

> Maryland's Sanaria is leveraging a logistics partnership with Cryoport to support its malaria vaccine development. More

> A centralized statewide reminder system for immunizations may be a more reliable way to increase overall vaccination rates, a new report says. More

And Finally... Pro-vaccine Facebook ($FB) founder Mark Zuckerberg is urging Facebook users to read a book about why people fear vaccination. More

Suggested Articles

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.